: Determinants of 12-month non-persistence (Cox model)
| Hazard Ratio | IC 95% | P-value | ||
|---|---|---|---|---|
| SC-TNFis | ||||
| GLM | 1.000 | – | – | – |
| CZP | 1.642 | 1.343 | 2.006 | <0.0001 |
| ETA | 1.512 | 1.297 | 1.763 | <0.0001 |
| ADA | 1.418 | 1.258 | 1.599 | <0.0001 |
| Sex | ||||
| Male | 1.000 | – | – | – |
| Female | 1.610 | 1.367 | 1.897 | <0.0001 |
| Age | 1.000 | 0.998 | 1.003 | 0.6833 |
| Deprived socio-economic status : Yes vs No | 0.901 | 0.712 | 1.141 | 0.3882 |
| Number of comorbid conditions (per additional condition) | 1.122 | 1.086 | 1.160 | <0.0001 |
| Biotherapy line (per additional line) | 1.364 | 1.296 | 1.435 | <0.0001 |
| DMARD dispensation: Yes vs No | 0.952 | 0.884 | 1.025 | 0.1924 |
| Sulfasalazine dispensation : Yes vs No | 1.101 | 0.964 | 1.258 | 0.1545 |
| Long term oral steroids : Yes vs No | 1.026 | 0.958 | 1.099 | 0.4629 |
| Hospital admission for IRMD | 0.932 | 0.871 | 0.997 | 0.0419 |
| Visits to rheumatologist | ||||
| 0 | 1.000 | – | – | – |
| 1–4 | 0.681 | 0.578 | 0.803 | <0.0001 |
| >4 | 0.704 | 0.599 | 0.828 | <0.0001 |
| Interaction with time | ||||
| Interaction biotherapy * time | 1.001 | 1.000 | 1.001 | 0.0025 |
| Interaction sex * time | 0.999 | 0.998 | 0.999 | 0.0023 |
| Interaction socio-economic status * time | 1.002 | 1.000 | 1.003 | 0.0084 |